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Abstract
The risk of postnatal HIV transmission exists throughout the breastfeeding period. HIV shedding in breast milk beyond six months has
not been studied extensively. The aim of this study was to determine prevalence and determinants of HIV shedding in breast milk
during continued breastfeeding
A cross-sectional study was nested in the PROMISE-PEP trial in Lusaka, Zambia to analyze breast milk samples collected from
both breasts at week 38 post-partum (mid-way during continued breastfeeding). We measured concurrent HIV deoxyribonucleic
acid (DNA) and HIV ribonucleic acid (RNA) as proxies for cell-associated HIV (CAV) and cell-free HIV (CFV) shedding in breast milk
respectively. Participants’ socio-demographic date, concurrent blood test results, sub clinical mastitis test results and contraceptive
use data were available. Logistic regression models were used to identify determinants of HIV shedding in breast milk (detecting
either CAV or CFV).
The prevalence of HIV shedding in breast milk at 9 months post-partum was 79.4% (95%CI: 74.0 – 84.0). CAV only, CFV only and
both CAV and CFV were detectable in 13.7%, 17.3% and 48.4% mothers, respectively. The odds of shedding HIV in breast milk
decreased significantly with current use of combined oral contraceptives (AOR: 0.37; 95%CI: 0.17 – 0.83) and increased significantly
with low CD4 count (AOR: 3.47; 95%CI: 1.23 – 9.80), unsuppressed plasma viral load (AOR: 6.27; 95%CI: 2.47 – 15.96) and severe
sub-clinical mastitis (AOR: 12.56; 95%CI: 2.48 – 63.58).
This study estimated that about 80% of HIV infected mothers not on ART shed HIV in breast milk during continued breastfeeding.
Major factors driving this shedding were low CD4 count, unsuppressed plasma viral load and severe sub-clinical mastitis. The inverse
relationship between breast milk HIV and use of combined oral contraceptives needs further clarification. Continued shedding of CAV
may contribute to residual postnatal transmission of HIV in mothers on successful ART.
Abbreviations: mL = microliter, 3TC = lamivudine, ANRS = National Agency for Research on AIDS and Viral Hepatitis, AOR =
adjusted odds ratio, ART = antiretroviral treatment, ARV = antiretroviral, BMC = breast milk cell, CAV = cell-associated HIV, CD4 =
cluster of differentiation 4, CFV = cell-free HIV, CI = confidence interval, DNA = Deoxyribonucleic Acid, EBF = exclusive
breastfeeding, g = gravitational force, HIV = human immunodeficiency virus, IBM = international business machine, INSERM =
National institute for Health and Medical Research, IQR = inter quantile range, IRB = Institution Review Board, K+ = Potassium, mL =
milliliter, Na+ = Sodium, oC= degrees Celsius, OR= odds ratio, PBS= phosphate buffered saline, PCR= polymerase chain reaction,
PMTCT = prevention of mother to child transmission, PROMISE-PEP = promoting infant health and nutrition in Sub-Saharan Africa –
Peri Exposure Prophylaxis, r= correlation coefficient, RNA=Ribonucleic Acid, RT-PCR=Reverse Transcriptase - Polymerase Chain
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1. Introduction
National health authorities in Zambia principally promote and
support breastfeeding and antiretroviral therapy (ART) as the
strategy that will most likely give infants born to HIV infected
mothers the greatest chance of HIV-free survival.[1] The country
has therefore adopted the World Health Organization (WHO)
recommendations to exclusively breastfeeding (EBF) for the first
six months and continued breastfeeding with supplementary
foods up to one year. Thereafter, extended breastfeeding until a
safe and nutritionally adequate diet can be provided for the
infant.[2] This is because EBF covers all nutritional and
immunological requirements of the newborn baby[3] and both
EBF and maternal ART promotes child survival.[4,5]
Both CAV and CFV have been associated with postnatal
transmission of HIV[6–8] with CAV thought to bemore important
in early breastfeeding while CFV was thought to be more
important in late breastfeeding.[9,10] Successful maternal ART
suppresses CFV but has little or no effect on CAV [11–13]implying
that breastfeeding infants are still exposed to CAV even in the
presence of successful ART. CFV in breast milk originates partly
from HIV replication in infected lymphocytes and macrophages
resident in mammary glands and partly from continued seeding
of systemic HIV particles across the mammary epithelial
layer.[6,14,15] CAV arise from local infections of mammary gland
permissive cells and recruitment of HIV infected cells migrating
from inducing sites of the mucosal immune system into the
mammary gland and subsequently in breast milk.[6,15] The mean
concentration of CAV per 106 BMC is lowest in colostrum[7] and
is thought to increase over time even in the presence of ART.[11,12]
Most studies looking at HIV-1 shedding in breast milk have
focused on the period up to six months postpartum[9,11,13,16–18]
and yet a substantial proportion of late postnatal transmission of
HIV-1 occurs beyond 6 months.[19,20] This leaves a knowledge
gap at a time developing infant is still at high risks of HIV-1
acquisition. Additionally, most studies looking at HIV shedding
in breast milk consider CFV and CAV separately. Considering
CFV and CAV separately has the potential to underestimate HIV
shedding in breast milk since some mothers who shed CFV may
not shed CAV and vice versa. The few studies that have looked at
HIV shedding beyond 6 months[7,8] used samples collected from
one breast and report cumulative prevalence rather than point
prevalence.
This study therefore seeks to determine prevalence of HIV
shedding based on both breasts and both CAV and CFV in breast
milk of HIV infected mothers not on ART. Our study will also
explore determinants of shedding either CAV or CFV in breast
milk during continued breastfeeding. This information is
important as we strive to eliminate postnatal transmission of
HIV since both CAV and CFV have been associated with late
postnatal transmission of HIV. Additionally, we have an
opportunity to study wild type HIV which would be unethical
in this era of universal ART.
2. Materials and methods
2.1. Study design, setting and sample size
This was an exploratory cross-sectional study nested in the
Zambian cohort of PROMISE PEP trial (NCT00640263)
conducted in Burkina Faso, South Africa, Uganda and Zambia
from November 16th, 2009 to May 7th, 2012. Its protocol[21]
and themain findings[19] have been published. Themain objective
of the study was to evaluate the efficacy and safety of infant pre-
exposure prophylaxis (PreP) using either Kaletra (Lopinavir /
Ritonavir) or Lamivudine (3TC) in infants breastfeeding from
HIV infected mothers. The trial included breastfeeding mothers
not eligible for ART at the time and their breastfeeding infants.
Mothers were asked to exclusively breastfeed for the first 6
months and thereafter continue breastfeeding with complemen-
tary foods. Theywere also advised to gradually wean their infants
by week 49. To prevent breastfeeding transmission of HIV,
infants were randomized to receive either Kaletra (Lopinavir /
Ritonavir) or Lamivudine (3TC) daily up to week 50 or 1 week
after cessation of breastfeeding. Potential participants were
approached during antenatal visits and those willing to
participate in the study were screened. After provision of
informed consent, eligible mothers-infant pairs were randomized
into the 2 arms of the trial (Kaletra and 3TC) at day 7 (±2) after
delivery. Follow up visits were set at week 2 and monthly
thereafter up to week 50. At each visit breastfeeding counseling
and support was provided. Health status of both the mother and
the infants were also assessed. Breast milk samples were collected
at day 7, week 6, week 14, week 26 and week 38 while blood
samples from the mother before delivery, day 7, week 14 and
week 38. At 7, week 6, week 14, week 26 and week 38 and week
50, dry blood spots samples were collected for early infant
diagnosis of HIV.
The source population for this sub study was the 563 mothers
randomized into PROMISE-PEP trial in Lusaka Zambia. Only
week 38 samples were included in this study as they were
collected mid-way during continued breastfeeding and were the
furthest available samples thereby maximizing the likelihood of
detecting HIV in breast milk as participating mothers took ARV
for PMTCT during pregnancy and delivery. Required sample size
to determine prevalence of HIV shedding was estimated to be 229
(assuming 50% prevalence and a design effect of 1) using open
source epidemiologic statistics for public health (OpenEpi)
version 3.1 updated on 6th April 2013 (www.OpenEpi.com)
sample size calculator.
2.2. Study participants and samples
Inclusion criteria for this sub study were:
a) provision of informed consent to store and use samples for
future research;
b) returning for week 38 follow-up visits;
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c) still breastfeeding at week 38; and
d) having week 38 breast milk samples from both breasts stored
at 80°C.
All mothers who met these criteria and had no missing data
(248) were included in the study
2.3. Sample collection and processing
Whole blood and breast milk samples were collected in the study
clinic and archived in the study laboratory during the PROMISE-
PEP trial. Both the clinic and the laboratory were located at the
University Teaching Hospital (UTH) in Lusaka. After breastfeed-
ing the baby and providing informed consent, mothers were
asked tomanually express aminimum of 10mL breast milk, from
each breast, into separate sterile 50mL conical centrifuge tubes
under supervision of a study nurse who also collected venous
blood immediately after milk expression.
During PROMISE-PEP trial, whole blood processing included
performing full blood, CD4 counts, Plasma viral load and storage
of plasma while breast milk processing included storage of breast
milk acellular fraction and breast milk cells (BMC) pellets.
Storage was done at 80°C within 24hours until further
laboratory analysis. For this sub study lactoserumHIVRNA load
and breast milk cell HIV DNA load were quantified as surrogate
makers of cell-free HIV (CFV) and cell-associated HIV (CAV) in
breast milk.
2.4. Quantification of HIV RNA in breast milk
To detect HIV RNA in breast milk, thawed left and right breast
milk acellular fractions were centrifuged at 1200g for 5 minutes
at room temperature to separate lactoserum from lipid layer.
Total RNA was extracted from 1mL of clear lactoserum using
QIAamp ultrasens virus kit (Qiagen, Hilden, Germany) andHIV-
1 RNA was quantified using Generic HIV-1 charge virale real
time RT-PCR kit (Biocentric, Bandol, France) and reported as
copies per milliliter (copies/mL). Results were categorized as
follow; ‘not detected’, ‘detected <50copies/mL’, ‘detected ≥ 50
copies/mL’ according to manufactures recommendations.
2.5. Quantification of HIV DNA in BMCs
To detect HIV DNA in BMCs thawed left and right dry breast
BMC pellets were re-suspended in 200mL of sterile DNase/
RNase-free PBS. Total DNAwas extracted from the re-suspended
pellets using QIAamp DNA mini kit (Qiagen, Hilden, Germany)
and quantified using a nanodrop spectrophotometer (Thermo
Scientific, Waltham, Massachusetts). HIV-1 DNA quantified
using Generic HIVDNA cell PCR kit (Biocentric, Bandol, France)
and reported as copies per 106 cells. Results were categorized as
‘not detected’ and ‘detected’ according to manufactures recom-
mendations.
2.6. Data collection and management
Breast milk laboratory results were entered into a database and
individually counterchecked to remove errors. Concurrent blood
tests results, sub clinical mastitis tests results, breastfeeding and
contraceptive use data were obtained from the PROMISE-PEP. A
mother was considered to shed CAV if HIV DNAwas detected in
at least one sample from either breast. Similarly, a mother was
considered to shed CFV if HIV RNA was detected in at least one
sample from either breast. Mothers were considered to shed HIV
if either HIV DNA or HIV RNA were detected in at least one
sample from either breast. Low CD4 count was defines as having
a CD4 count less than 500cells/mL while unsuppressed plasma
viral load was defined as ≥ 1000copies/mL. SCM status was
determined as negative (Na+/K+ ratio<0.6), mild SCM (Na+/K+
ratio between 0.6 and 1) and severe SCM (Na+/K+ ratio >1).
Contraceptive data was by self-report using a questionnaire and
mothers grouped as follows; oral contraceptives, injectable
contraceptives and non-hormonal or no contraceptive used
2.7. Statistical analysis
All statistical tests were two-tailed with statistical significance at P
< .05. Confidence level was set at 95% and power at 80%. For
continuous variables either the mean with 95% confidence
interval (CI) or median with inter-quartile range (IQR) were
reported depending on whether the variable was normally
distributed or not. Percentages were reported for categorical
variables. Spearman’s rho was used to measure correlation
between continuous variables. Paired t test was used to compare
means after log10 transformation while Pearson Chi-Square test
was used to compare proportions.
Multinomial and binary logistic regression models were used
to identify potential factors associated HIV shedding in breast
milk. Bivariable analysis with an interaction term was done to
assess interaction between variables. Multivariable logistic
regression models were constructed to determine factors
significantly associated with HIV shedding in breast milk. In
each model, all variables associated with the dependent variables
(P< .20) were included in final multivariable models (method:
enter). Analysis was repeated using CFV shedding and CAV
shedding as outcome variables to identify which component is
affected. Less than 10% of eligible mothers had missing data and
were excluded from the analysis. Statistical analysis was done
using statistical package for social sciences (SPSS) version 20
(IBM Corporation, Armonk, New York) and open source
epidemiologic statistics for public health (OpenEpi) version 3.1
updated on 06th April 2013 (www.OpenEpi.com).
2.8. Ethical considerations
This sub study analyzed archived samples from the PROMISE-
PEP trial. The trial was approved by the University of Zambia
biomedical Research Ethics Committee (IRB No. 00001131 of
IORG 0000774; FWA No. 00000338). Approval for this sub
study was obtained from the scientific committee of PROMISE
PEP trial, ERS CONVERGE Institution Review Board (IRB No.
00005948; FWA No. 00011697) and the Regional Committee
for Medical Research Ethics of Norway (REK Nord no
200802523-2) approved the study protocol. All participating
mothers gave written informed consent during the main trial for
storage and future use of their samples in research.
3. Results
3.1. Participants’ characteristics
During the PROMISE-PEP trial, 563 breastfeeding infants were
randomized in Lusaka, Zambia,. Of the 315 mothers who were
still breastfeeding at week 38, 270 had breast milk samples from
both breasts stored at80oC and therefore eligible to participate
in this study. Of these eligible mothers, 22were excluded from the
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study due to missing data resulting in a sample size of 248
mothers. Each mother contributed 2 samples (1 from each breast)
resulting in 496 breast samples analyzed.
Participants’ characteristics are summarized inTable 1.Mothers
participating in this study had amedian age of 26.5 years (IQR: 23
– 32), a median parity of 3 (IQR: 2 – 4) and a mean CD4 count of
660cells/mL (95%CI: 632 – 688). Although three-quarter (75.1%)
had normal CD4 count (≥ 500cells/mL), only a few (10.9%) had
suppressed HIV-1 plasma viral load (< 1000copies/mL). Among
mothers with detectable plasma viral load, the mean log10 plasma
viral load was 4.6copies/mL (95%CI: 4.5 – 4.7).
3.2. HIV shedding in breast milk during continued
breastfeeding
Breast milk CFV was not detected, detected <50copies/ml, and
detected ≥ 50copies/ml, in 85 (34.3%; 95%CI: 28.6 – 40.4),
45 (18.1%; 95%CI: 13.8 – 23.4) and 118 (47.6%; 95%CI: 41.4
– 53.8) mothers, respectively. Bilateral CFV detection (detectable
in both breasts) was observed in 60.7% of the mothers with
detectable CFV and there was positive correlation between CFV
load in left and right breasts (r=0.583; P< .001). Breast milk
CFV load positively correlated with concurrent plasma viral load
(r=0.450; P< .001) and breast milk CAV load (r=0.422;
P< .001). Contrary, breast milk CFV load negatively correlated
with CD4 count (r=0.340; P< .001). Among samples with
detectable CFV, the mean log10 breast milk HIV RNA load was
2.2 (95%CI: 2.1 – 2.3).
Breast milk CAV was detected in 154 (62.1%; 95%CI: 55.9 –
67.9) mothers. Bilateral CAV detection was observed in 59.7%of
the mothers with detectable CAV. There was a positive
correlation between CAV load in left and right breast milk
samples (r=0.348; P< .001). Breast milk CAV load correlated
positively with plasma viral load (r=0.198; P< .001) and
negatively with CD4 count (r= - 0.211; P< .001). Among
samples with detectable breast milk CAV, the mean log10 breast
milk DNA load was 1.4 (95%CI: 1.2 – 1.5).
A total of 197 mothers had detectable CAV or CFV (shedders)
translating into a 79.4% (95%CI: 74.0 – 84.0) prevalence of
HIV shedding in breast milk. Of the shedders, 34 (13.7%) shed
CAV only, 43 (17.3%) and the remaining 120 (48.4%) shed both
CAV and CFV [120 in at least one sample (Table 2). We did not
detect neither CAV nor CFV in any breast milk sample from both
breasts in 20.6% (95%CI: 16.0 – 26.0) mothers (non-shedders).
3.3. Determinants of HIV shedding in breast milk during
continued breastfeeding
Multivariable analysis of our data show that HIV shedding
(detecting either CAV or CFV) in breast milk is positively
associated with low CD4 count (AOR: 3.47; 95%CI: 1.23 –
9.80), unsuppressed plasma viral load (AOR: 6.27; 95%CI: 2.47
– 15.96) and severe SCM (AOR: 12.56; 95%CI: 2.48 – 63.58).
We also report an independent negative association between HIV
shedding in breast milk with concurrent use of combined oral
contraceptive (AOR: 0.37; 95%CI: 0.17 – 0.83) (Table 3).
To determine factors significantly associated with each
component of HIV in breast milk, we constructed separate
multivariable regression models for CFV shedding (Table 4) and
CAV shedding (Table 5) as outcome variables. We found that
shedding CFV ≥ 50copies/mL in breast milk was positively
associated with anemia, mild SCM, severe SCM, detectable CAV,
low CD4 count and unsuppressed plasma viral load. Contrary,
the odds of shedding CFV ≥ 50copies/mL was negatively
associated with concurrent use of combined oral contraceptives.
Last, Mothers of female infants tended to shed more CFV
compared to those with male infants but the association did not





Age groups in years
 24 87 35.1%
25 – 29 76 30.6%
30 – 34 47 19.0%
≥ 35 38 15.3%
Parity
Para 1–2 120 48.3%
Para 3–4 108 43.6%








0–6 years 79 31.9%
7–11 years 133 53.6%














≥ 500 cells/mL 186 75.0%
 499 cells/mL 62 25.0%
HIV plasma viral load
 1000 copies/mL 27 10.9%
≥ 1001 copies/mL 221 89.1%
SCM status (Na+/K+ ratio)
Negative (< 0.6) 144 58.1%
Mild (0.6–1) 59 23.8%
Severe (> 1) 45 18.1%
HB=hemoglobin, HIV=human immunodeficiency virus, SCM= subclinical mastitis.
Table 2
Breast milk HIV shedding categories (n=248).
Status Frequency Percent 95% CI
Neither cell free nor cell associated HIV detected 51 20.6% 16.0–26.0
Only cell-associated HIV detected 34 13.7% 10.0–18.5
Only cell-free HIV detected 43 17.3% 13.1–22.5
Both cell free and cell associated HIV detected 120 48.4% 42.2–54.6
CI= confidence interval, HIV=human immunodeficiency virus.
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Table 3
Factors associated with shedding any HIV-1 in breast milk (n=248).
Crude estimates Adjusted estimates
Predictors OR 95% CI P AOR 95% CI P
Combined oral contraceptive
No 1.00 1.00
Yes 0.53 0.26–1.09 .085 0.37 0.17–0.83 .015
Injectable contraceptive
No 1.00
Yes 1.41 0.62–3.24 .414
Haemoglobin concentration
≥ 12 g/dL 1.00 1.00
 11 g/dL 1.67 0.80–3.47 .170 1.29 0.58–2.85 .530
CD4 count
≥ 500 cells/mL 1.00 1.00
 499 cells/mL 3.75 1.42–9.91 .008 3.47 1.23–9.80 .019
Plasma viral load
 1000 copies/mL 1.00 1.00
≥ 1001 copies/maL 5.37 2.33–12.32 < .001 6.27 2.47–15.96 < .001
SCM status (Na+/K+ ratio)
Negative (< 0.6) 1.00 1.00
Mild (0.6–1) 1.35 0.65–2.83 .419 1.54 0.69–3.42 .288
Severe (> 1) 7.44 1.72–32.21 < .001 12.56 2.48–63.58 .002
AOR=adjusted odds ratio, CI= confidence interval, HIV=human immunodeficiency virus, OR= odds ratio, SCM= sub-clinical mastitis.
Table 4
Factors associated with detection of cell-free HIV load ≥ 50 copies/mL in breast milk (n=248).
Crude estimates Adjusted estimates
Predictors OR 95% CI P AOR 95% CI P
Combined oral contraceptive
No 1.00 1.00
Yes 0.52 0.26–1.04 .063 0.38 0.17–0.86 .020
Injectable contraceptive
No 1.00
Yes 1.04 0.51–2.12 .905
Child’s Gender
Boys 1.00 1.00
Girls 1.57 0.90–2.75 .115 1.93 0.96–3.79 .055
Parity
Multiparity 1.00 1.00
Primiparity 0.58 0.27–1.24 .163 0.52 0.22–1.26 .146
Haemoglobin concentration
≥ 12 g/dL 1.00 1.00
<12 g/dL 2.38 1.26–4.50 .008 2.09 1.00–4.35 .049
CD4 count
≥ 500 cells/mL 1.00 1.00
 499 cells/mL 5.32 2.34–12.08 < .001 5.22 2.05–13.28 .001
Plasma viral load
 1000 copies/mL 1.00 1.00
≥ 1001 copies/mL 5.74 2.19–15.03 < .001 5.23 1.72–15.91 .004
SCM status (Na+/K+ ratio)
Negative (< 0.6) 1.00 1.00
Mild (0.6–1) 2.12 1.06–4.24 .033 2.86 1.26–6.49 .012
Severe (> 1) 3.76 1.64–8.62 .002 3.27 1.19–9.03 .022
Breast milk HIV DNA
Not detected 1.00 1.00
Detected 4.82 2.63–8.85 < .001 3.54 1.75–7.20 < .001
AOR=adjusted odds ratio, CI= confidence interval, DNA=deoxyribonucleic acid, HIV=human immunodeficiency virus, OR= odds ratio, SCM= sub-clinical mastitis.
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breast milk was positively associated with detecting breast milk
CFV<50copies/mL, detecting breast milk CFV ≥ 50copies/mL
and severe SCM.
4. Discussion
Our results indicate that 79.4% (95%CI: 74.0 – 84.0) of HIV
infected mothers shed HIV in breast milk in the absence of ART
during continued breastfeeding. As expected, the prevalence of
HIV shedding in late breast milk when considering both CAV and
CFV is significantly higher than prevalence estimates based on
either CAV alone [62.1% (95%CI: 55.9%–67.9%) or CFV alone
[65.7% (95%CI: 59.6%–71.4%), however prevalence estimates
based on CAV alone and CFV alone did not differ significantly.
Our estimates of CAV and CFV shedding are in line with earlier
studies in the region.[7,8]
Our results also confirm earlier findings that CD4 count,
plasma viral load, and subclinical mastitis are independently
associated with HIV shedding in breast milk. In addition to these
known determinants, we also found an independent significant
negative association between concurrent use of combined oral
contraceptive and HIV-1 shedding in breast milk. Of the
identified determinants, only subclinical mastitis affects both
CFV and CAV shedding and severe SCM, as an indicator of
mammary gland inflammation, is by far the most important
determinant HIV shedding in breast milk. Our results also
indicate that whereas severe SCM is associated with both CFV
and CAV, mild SCM is only associated with CFV and has no
effect on CAV.
This study was done prior to the introduction of life-long ART
for all in Zambia. Since 2016 all pregnant and lactating women
living with HIV are started on ART for life (option B+), thus,
study participants were not on ART according to national
guidelines at the time. Conducting such a study currently would
be unethical as all breastfeeding mothers are now supposed to be
on ART. Although our results cannot be extrapolated to mothers
on ART, they provide some kind of baseline data on wild type
HIV that studies on mothers on ART can compare with. Our
results however would apply to breastfeeding mothers still not on
ART despite option B+ implementation due to suboptimal
retention[22,23] or poor coverage in some places.[24] Latest
estimates by UNAIDS reported that half of the pediatric HIV
infection post-partum could be attributable to mother not
on ART.
Despite not being on ART for several months (9 months), we
could not detect any HIV (CAV or CAV) in breast milk samples
from both breasts of about 20% mothers, suggesting some
mothers naturally do not shed HIV in breast milk and therefore
their infants may not be exposed to breast milkHIV.Mechanisms
governing this resistance to HIV shedding in breast milk are not
known. Nevertheless, our results suggest that maternal systemic
HIV and sub clinical mastitis, an indicator of mammary gland
inflammation, may be involved. Therefore, control of mammary
gland inflammation and suppression of systemic HIV may
minimize HIV shedding in breast milk.
Our results showed that in the absence of ART, there was a
significant positive association between CAV andCFV suggesting
local replication ofHIV in themammary gland. Indeedmammary
gland CD4 cells and macrophages are more immunologically
activated than their blood counterparts making them more
permissive to HIV infection and replication.[6] This association is
disrupted in mothers on successful ART which suppresses CFV
but has little or no effect on CAV[11,12] explaining why studies
looking at mothers on ART fail to find significant association
between CAV and CFV.[11]
Previous studies have reported association between plasma
viral load and breast milk CAV[7,9] but these studies did not take
into account breast milk CFV. In our study, breast milk CAVwas
significantly associated with plasma viral load and CD4 count in
univariate analysis. Controlling of milk CFV attenuated this
Table 5
Factors associated with detection of cell-associated HIV in breast milk (n=248).
Crude estimates Adjusted estimates
Predictors OR 95% CI P AOR 95% CI P
Combined oral contraceptive
No 1.00
Yes 0.71 0.37–1.34 .289
Injectable contraceptive
No 1.00
Yes 0.86 0.45–1.62 .639
CD4 count
≥ 500 cells/mL 1.00 1.00
 499 cells/mL 2.08 1.10–3.93 .025 1.37 0.67–2.77 .387
Plasma viral load
 1000 copies/mL 1.00 1.00
≥ 1001 copies/mL 2.25 1.00–5.04 .049 1.61 0.63–4.11 .324
SCM status (Na+/K+ ratio)
Negative (< 0.6) 1.00 1.00
Mild (0.6–1) 1.12 0.61–2.06 .719 0.94 0.49–1.81 .843
Severe (> 1) 8.43 2.87–24.78 < .001 7.36 2.39–22.67 .001
Breast milk HIV RNA
Not detected 1.00 1.00
Detected <50 copies/mL 3.00 1.41–6.39 .004 2.75 1.23–6.16 .014
Detected ≥ 50 copies/mL 4.82 2.63–8.84 < .001 3.66 1.86–7.20 < .001
AOR= adjusted odds ratio, CI= confidence interval, HIV=human immunodeficiency virus, OR= odds ratio, RNA= ribonucleic acid, SCM= sub-clinical mastitis.
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association thereby, indicating that the effect of systemic HIV on
breast milk CAV is through breast milk CFV. Since CAV persist
in breast milk beyond six months, breastfeeding infants therefore
remain at risk of CAV related HIV acquisition[6,7,9,25] even in the
presence of successful maternal ART. Additionally, studied on
breastfeeding mothers on successful ART have reported episodic
detection of CFV in their breast milk over time[11] which puts
breastfeeding infants at risk of HIV acquisition too. Therefore,
supplementing maternal ART with infant ARV prophylaxis,
which is effective against both CFV and CAV[6,19] mediated HIV
acquisition, for the entire breastfeeding period, may be more
effective in eliminating residual postnatal transmission of HIV.
Our results suggest that COC may inhibit CFV shedding in
breastmilk. COCcontains synthetic estrogen andprogestin. In our
study progestin-only ICs were neither associated with CAV nor
CFV in breast milk. Our results therefore, suggest that the
inhibitory effect of COC on breast milk CFV may be due to
estrogen. Since the rate of detectingHIV-1 in plasma (P= .638) did
not differ significantly between COC users and non-users, our
results also suggest that estrogen selectively inhibits HIV-1 in the
mammary gland. Earlier studies reported a similar tissue specific
inhibitory effect of estrogen on HIV-1 replication in the cervico-
vaginal tract despite similar plasma viral load.[26] Literature
indicates that estrogen inhibits HIV-1 replication by suppressing
HIV-1 long terminal repeats (LTR) promoter activity[27,28] thereby
inhibiting HIV-1 transcription and by reducing susceptibility of
CD4+ lymphocytes and macrophages to HIV-1 infection.[29,30]
Further studies are needed to confirm this association.
Infant sex has not been previously associated with CFV
shedding in breast milk. Although marginally significant (P
= .055), our study suggests that mothers of female infants may
shed more breast milk CFV compared to those of male infants.
Recent findings indicate that infant’s gender may influence the
composition of human breast milk[31–33] and breastfeeding
practice,[34] both of which would affect HIV shedding in breast
milk. In line with our findings, earlier studies[35,36] reported
higher risks of early postnatal acquisition of HIV in female
infants. This was attributed to possible higher susceptibility to
HIV infection in female infants than inmales arising from genetic,
immunological, hormonal and environmental factors.[35] Our
results provide an additional mechanism to explain higher rates
of postnatal HIV transmission in female infants. However,
contrary to our results, a large meta-analysis[37] reported
significantly higher risks of late postnatal acquisition of HIV
in male infants. This study, however, did not consider maternal
plasma viral load thereby ignoring an important confounder to
this association.
Our study had several strengths. Firstly, our study had largest
number of breast milk samples collected at the same time point
compared to similar studies. Secondly, HIV shedding was
estimated based on both breasts and both CAV and CFV thereby
giving a true reflection of HIV shedding in breast milk. Thirdly, a
rigorous sampling and randomization process in the parent trial
means that we had representative sample and confounders were
dealt with. Lastly, mothers included in this study were not on
ART therefore it would not be possible to conduct such a study
currently. Limitations of our study were, firstly, this was a
secondary analysis of a trial designed for a different purpose.
Secondly, contraceptive use data was collected by self-report.
However, this data was collected during family planning
counseling at each monthly visit and therefore mothers were
very familiar contraceptive methods. Thirdly, study participants
were selected from a cohort of HIV-1 infected breastfeeding
mothers with high CD4+ count and not on ART. Therefore, our
results may not be extrapolated to mothers on ART or with low
CD4 count. This being a cross sectional study, the causal nature
of the association between HIV shedding and its determinants
could not be assessed. Lastly wide confidence intervals for some
of our estimates may indicate the need for a larger sample size to
improve accuracy of our estimates.
This study estimated that about 80% of HIV infected mothers
not on ART shed HIV in breast milk during continued
breastfeeding. Major factors driving this shedding were low
CD4 count, unsuppressed plasma viral load and severe sub-
clinical mastitis. The inverse relationship between breast milk
HIV and use of combined oral contraceptives needs further
clarification. Continued shedding of CAV may contribute to
residual postnatal transmission of HIV in mothers on
successful ART.
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